Tagraxofusp
Elzonris
Near Add Your Location
Accepting patients
SL-401
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 1
Accepting patients
Tagraxofusp
CD123 Antibody Toxin Congregate (CD123 ATC; Tagraxofusp) Combined With Azacitidine for Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for Patients With CD123-Positive Malignant
- CD123
- Post-Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
Tagraxofusp in Combination With Decitabine
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
- CD123
- Phase 1/2
Accepting patients
Tagraxofusp for Post-Transplant Maintenance
Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelofibrosis and Chronic Myelomonocytic Leukemia
- CD123
- Maintenance
- Post-Allogeneic Stem Cell Transplant
- Phase 1
Showing 1-4 of 4